A new AI model is opening the black box of the leading artificial intelligence tool for predicting how proteins will interact with small molecules, such as drugs. The model, OpenFold3, which launched ...
Researchers at Baylor College of Medicine have developed an artificial intelligence (AI) model that reveals how protein modifications link genetic mutations to disease. The method, called DeepMVP and ...
For the field of drug development, hitting the right target with atomic precision to achieve therapeutic effect remains the core challenge. While traditional R&D pipelines are dependent on ...
Hosted on MSN
AI model predicts peptide sequences that prevent ribosome stalling in E. coli protein production
Proteins sourced from microorganisms are attracting attention for their potential in biomanufacturing a variety of products, including pharmaceuticals, industrial enzymes, and diagnostic antibodies.
An MIT-developed AI model has designed dozens of lab-confirmed protein binders for targets long considered out of reach, offering a new tool for drug discovery and ...
Genesis’ proprietary foundation model – Pearl – outperforms frontier models, including AlphaFold 3, on key benchmarks that predict utility in real-world drug discovery Pearl’s performance improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback